ACE2 and COVID-19: On the other hand, there is some evidence that therapeutic doses of RAAS blockers in humans may lead to upregulation and overexpression of ACE2 at the cell surface, increasing the susceptibility to COVID-19.4 Recently, Hamet et al also suggested an association between ACE2 polymorphism and severity of outcomes to COVID-19.